I. Evans

Oxaliplatin Compromised CDK1 Activity Sensitizes BRCA-Proficient Cancers to PARP Inhibition in Oxaliplatin Resistance Gastric Cancer

A. Behrens, Wei Chen, Yulong He, 2021 .

PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway

J. Oliveira, A. Behrens, Wei Chen, 2021, Frontiers in Cell and Developmental Biology.

Prognostic markers in node‐negative breast cancer: A prospective study

T. Kute, E. Tucker, S. Johnston, 2004, Cytometry. Part B, Clinical cytometry.

METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability

J. Oliveira, A. Behrens, Wei Chen, 2022, Cellular and Molecular Life Sciences.

Ductal Ngn3-expressing progenitors contribute to adult β cell neogenesis in the pancreas

A. Behrens, H. Heimberg, C. Lambert, 2021, Cell stem cell.

USP7 controls NGN3 stability and pancreatic endocrine lineage development

J. Nelson, K. Hansson, Axel Behrens, 2023, Nature communications.